GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat…
An institutional-grade, numbers-driven thesis on GSK — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates GSK plc (GSK) 61/100 with a 12-month base-case forecast of $52.45 — -1.0% versus the current price of $52.96. GSK plc trades at $52.96 in the Healthcare sector, with a market capitalisation of $106.11B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for GSK is $52.45, implying -1.0% versus the current price. The model's 12-month scenario range runs from $67.39 (bear) to $77.24 (bull), with a base case of $70.48.
On the fundamentals, GSK shows a P/E of 16.3, trailing revenue of $32.67B, revenue growth of +4.1% YoY, a dividend yield of 3.42%. This page also tracks GSK's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
GSK currently carries a TradersQuant composite score of 61/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Hold". Our 12-month price target of $52.45 implies -1.0% from $52.96. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for GSK is $52.45, about -1.0% versus the latest price of $52.96. Consensus is based on 29 analysts.
TradersQuant's 12-month model forecast for GSK is a base case of $70.48, ranging from $67.39 (bear) to $77.24 (bull), an expected return of +33.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for GSK over the next 12 months is $70.48 in the base case (bear $67.39, bull $77.24), versus today's price of $52.96. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for GSK — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates GSK's fair value at $52.45, implying -1.0% of expected upside versus the current price.
Yes — GSK pays a dividend yielding 3.42% (about $1.81 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
